http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2422204-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166 |
| filingDate | 2005-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_131f78fe2d3d98ef99370a2f81f6f829 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edc10b04822c920f328361a2b1b275cc |
| publicationDate | 2013-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2422204-T3 |
| titleOfInvention | Novel derivatives of imidazolidin-2-one as selective androgen receptor modulators (SARMS) |
| abstract | A compound of formula (I) ** Formula ** R1 is hydrogen; R2 is C1-4alkyl or C1-4alkyl substituted with halogen and R3 is carboxy, -C (O) - (C1-4alkoxy), -C (O) -N (RB) 2; wherein each RB is independently selected from hydrogen, C1-4alkyl, and aryl, provided that if present, only one RB is aryl; wherein aryl is optionally substituted with one or more independently selected substituents of halogen, hydroxy, carboxy, C1-4alkyl, halogen substituted C1-4alkyl, C1-4alkoxy, C1-4alkoxy substituted with halogen, cyano, nitro, amino, C1-4alkyl-amino or di (C1-4alkyl) amino; R4 is selected from the group consisting of halogen, hydroxy, carboxy, C1-4alkyl, C1-4alkyl substituted with halogen, C1-4alkoxy, C1-4alkoxy substituted with halogen, cyano, nitro, amino, C1-4alkyl- amino, di (C1-4alkyl) amino, -C (O) - (C1-4alkyl), -C (O) - (C1-4alkoxy), -C (O) -N (RA) 2, - S (O) 0-2- (C1-4alkyl), -SO2-N (RA) 2, -N (RA) -C (O) - (C1-4alkyl), -N (RA) -C ( O) (C1-4 alkyl substituted with halogen) and aryl; wherein each RA is independently selected from hydrogen or C1-4alkyl; wherein aryl is optionally substituted with one or more independently selected substituents of halogen, hydroxy, carboxy, C1-4alkyl, halogen substituted C1-4alkyl, C1-4alkoxy, C1-4alkoxy substituted with halogen, cyano, nitro, amino, C1-4alkyl-amino or di (C1-4alkyl) amino; a is an integer from 0 to 4; b is 0; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 2004-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.